Physician profile
Michael W Delaney
NPI 1710157920
$16,751.28
in general payments reported to CMS, 2019-2025
67 companies · $3,719 in 2025
The $3,719 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $1,475 · 2021: $1,891 · 2022: $1,576 · 2023: $2,468 · 2024: $3,533 · 2025: $3,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,719.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,186.67 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $1,538.04 | 2020-2025 | Briviact, Nayzilam, Zilbrysq |
| Sunovion Pharmaceuticals INC. | $1,432.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,073.21 | 2019-2025 | |
| Biogen, INC. | $831.41 | 2019-2025 | Vumerity, Qalsody, Spinraza |
| Lilly USA, LLC | $723.75 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Allergan, INC. | $533.12 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $527.63 | 2023-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $466.85 | 2020-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $453.77 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $404.50 | 2019-2025 | Rytary, Crexont |
| Emd Serono, INC. | $398.93 | 2019-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $394.10 | 2023-2025 | |
| Eisai INC. | $341.80 | 2020-2025 | |
| Neurelis, INC. | $341.02 | 2020-2025 | Valtoco |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Delaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.